Hesperetin attenuates sepsis-induced intestinal barrier injury by regulating neutrophil extracellular trap formation via the ROS/autophagy signaling pathway

被引:2
|
作者
Chen, Fang [1 ,2 ]
Chu, Chengnan [3 ]
Wang, Xinyu [3 ,4 ]
Yang, Chao [3 ,4 ]
Deng, Yunxuan [3 ,4 ]
Duan, Zehua [3 ,4 ]
Wang, Kai [3 ,4 ]
Liu, Baochen [3 ,4 ]
Ji, Wu [3 ,4 ]
Ding, Weiwei [1 ,2 ,3 ,4 ]
机构
[1] Southeast Univ, Jinling Hosp, Sch Med, Nanjing, Peoples R China
[2] state Key Lab Trauma Burn & Combined Injury, Nanjing, Peoples R China
[3] Nanjing Univ, Jinling Hosp, Affiliated Hosp, Res Inst Gen Surg,Div Trauma,Med Sch, Nanjing 210002, Jiangsu, Peoples R China
[4] Nanjing Univ, Jinling Hosp, Res Inst Gen Surg, Surg Intens Care Unit,Affiliated Hosp,Med Sch, Nanjing 210002, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
OXIDATIVE STRESS; IN-VIVO; AUTOPHAGY; RAT; DEFINITIONS; DAMAGE; GUT; ROS;
D O I
10.1039/d2fo02707k
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Hesperetin (HES), one of the major flavonoids that has various biological activities, such as anti-inflammatory and antioxidant activities, may preserve the intestinal barrier during sepsis. However, the detailed mechanism remains unclear. Our previous studies confirmed that neutrophil extracellular traps (NETs) may jeopardize the intestinal barrier via a reactive oxygen species (ROS)-dependent pathway during sepsis. Therefore, we hypothesized that HES may inhibit NET formation and protect the intestinal barrier function during sepsis. Methods: Mice were pretreated with HES (50 mg kg(-1)) intraperitoneally for one week, and sepsis models were then induced using lipopolysaccharides (LPS) (10 mg kg(-1)). The mice were randomly divided into three groups: (1) sham group; (2) LPS group; and (3) HES + LPS group. Twenty-four hours after LPS injection, the serum and terminal ileum specimens were collected for subsequent studies. To detect ROS production and NET formation in vitro, human neutrophils were collected and incubated with phorbol-12-myristate-13-acetate (PMA) and various concentrations of HES. The level of autophagy was measured by an immunofluorescence assay and western blot analysis. TUNEL staining was utilized to analyze cell apoptosis. Results: The outcomes demonstrated that HES decreased inflammatory cytokine and myeloperoxidase (MPO) levels in serum and attenuated distant organ dysfunction in LPS-induced septic mice. Meanwhile, HES treatment reversed intestinal histopathological damage in septic mice, improving intestinal permeability and enhancing tight junction expression. Moreover, we found that neutrophil infiltration and NET formation in the intestine were suppressed during sepsis after HES pretreatment. In vitro, HES treatment reduced PMA-induced ROS production and NET formation, which were reversed by hydrogen peroxide (H2O2) administration. Notably, HES also inhibited NET formation by reducing the microtubule-associated protein light chain 3 (LC3)-II/LC3-I ratio (an indicator of autophagy) in PMA-induced neutrophils, which was reversed by rapamycin. Moreover, when autophagy was suppressed by chloroquine or induced by rapamycin, apoptosis in cells will be switched with autophagy. Conclusion: Taken together, these findings suggest that HES may inhibit NET formation in a ROS/autophagy-dependent manner and switch neutrophil death from NETosis to apoptosis, which reduced NETs-related intestinal barrier damage, providing a novel protective role in intestinal barrier dysfunction during sepsis.
引用
收藏
页码:4213 / 4227
页数:15
相关论文
共 50 条
  • [1] Magnesium hydride attenuates intestinal barrier injury during hemorrhage shock by regulating neutrophil extracellular trap formation via the ROS/ MAPK/PAD4 pathway
    Cao, Changkui
    Yu, Pan
    Chu, Chengnan
    Wang, Zhenjie
    Xu, Weiqi
    Cheng, Feng
    Zhao, Heng
    Qiu, Zhaolei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 130
  • [2] Remifentanil attenuates sepsis-induced intestinal injury by inducing autophagy
    Wang, Mingli
    Guo, Shiqi
    Zhang, Yu
    Zhang, Yao
    Zhang, Hong
    BIOENGINEERED, 2021, 12 (02) : 9575 - 9584
  • [3] Rosavin inhibits neutrophil extracellular traps formation to ameliorate sepsis-induced lung injury by regulating the MAPK pathway
    Gao, Tianwei
    Li, Juan
    Shi, Lei
    Hu, Bo
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2023, 51 (04) : 46 - 54
  • [4] Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation
    Yang, Kai
    Wu, Bin
    Wei, Wu
    Li, Cuiyu
    Li, Lu
    Cong, Zhukai
    Xiang, Qian
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 118
  • [5] Phellodendrine inhibits oxidative stress and promotes autophagy by regulating the AMPK/mTOR pathway in burn sepsis-induced intestinal injury
    Ding, Wei
    Qian, Kun
    Bao, Wenxiu
    Wang, Zhen
    TOXICOLOGY RESEARCH, 2025, 14 (01)
  • [6] Schisantherin A attenuates sepsis-induced acute kidney injury by suppressing inflammation via regulating the NRF2 pathway
    Gui, Yuan
    Yang, Youjing
    Xu, Deyu
    Tao, Shasha
    Li, Jianzhong
    LIFE SCIENCES, 2020, 258
  • [7] Cudratricusxanthone A attenuates sepsis-induced liver injury via SIRT1 signaling
    Lee, Yuri
    Jeong, Gil-Saeng
    Kim, Kyung-Min
    Lee, Wonhwa
    Bae, Jong-Sup
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (07) : 5441 - 5446
  • [8] Atorvastatin combined with imipenem alleviates lung injury in sepsis by inhibiting neutrophil extracellular trap formation via the ERK/NOX2 signaling pathway
    Zhang, Yue
    Wu, Di
    Sun, Qishun
    Luo, Zhen
    Zhang, Yuhao
    Wang, Bowei
    Chen, Wenting
    FREE RADICAL BIOLOGY AND MEDICINE, 2024, 220 : 179 - 191
  • [9] LncRNA Lethe protects sepsis-induced brain injury via regulating autophagy of cortical neurons
    Mai, C.
    Qiu, L.
    Zeng, Y.
    Jian, H-G
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (11) : 4858 - 4864
  • [10] Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling
    Xie, Shuhua
    Yang, Tao
    Wang, Zhifen
    Li, Man
    Ding, Ling
    Hu, Xiaotong
    Geng, Licheng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 78